Patent · US Active

Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity

US8211938B2 · kind B2 · utility

8Cited by
3References
13Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMar 2, 2010
Grant dateJul 3, 2012
Priority date
Expiry dateNov 8, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P21/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of treatment of native, non-denatured tissue to increase resistance to tearing, fissuring, rupturing, and/or delamination, comprising the step of: contacting at least a portion of the tissue with an effective amount of a reagent that increases crosslinks in the tissue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.